- Median overall survival reached 21.1 months with Imdelltra plus Imfinzi versus 12.7 months with Imfinzi alone in extensive-stage small cell lung cancer.
- Nearly 80% of patients on the combination were alive at one year versus 53% receiving Imfinzi alone, according to Amgen.
- The trial tested the combination as maintenance therapy after initial Imfinzi and chemotherapy in patients whose cancer had not progressed, with benefits seen across subgroups including patients with brain or liver spread.
- Imdelltra posted $288 million in Q2 sales, up 115% year over year, and generated $627 million in global sales in 2025.
Quotes
“I think there are moments in medicine when you see a piece of data that is so profound that it's going to transform the standard of care for patients, and I think, honestly, we're at that moment”
“has the potential to take on one of the most aggressive cancers that we deal with today, and almost convert it into a chronic disease”